HomeCSL • ASX
add
CSL Ltd
Previous close
$273.72
Day range
$275.00 - $278.81
Year range
$256.15 - $313.55
Market cap
133.87B AUD
Avg Volume
578.17K
P/E ratio
33.16
Dividend yield
1.01%
Primary exchange
ASX
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 3.37B | 10.14% |
Operating expense | 1.05B | 12.78% |
Net income | 370.50M | 29.77% |
Net profit margin | 10.98 | 17.81% |
Earnings per share | — | — |
EBITDA | 788.00M | 3.01% |
Effective tax rate | 20.28% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.66B | 7.04% |
Total assets | 38.02B | 4.93% |
Total liabilities | 18.62B | 1.16% |
Total equity | 19.40B | — |
Shares outstanding | 483.25M | — |
Price to book | 7.62 | — |
Return on assets | 4.22% | — |
Return on capital | 5.08% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | 370.50M | 29.77% |
Cash from operations | 847.50M | 4.57% |
Cash from investing | -278.50M | 22.53% |
Cash from financing | -235.00M | 43.37% |
Net change in cash | 316.00M | 1,139.22% |
Free cash flow | 348.19M | 93.30% |
About
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994. Wikipedia
Founded
1916
Headquarters
Website
Employees
32,698
